Medicine News Car T Cell Therapy Reaches Beyond Cancer Penn Medicine

Researchers Want to Test Whether CRISPR Screens Could Enhance CAR T Cells in Clinical Trials

Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying the hypotheses in humans. Read More

Penn professor Carl June discusses medical innovation award, CAR-T cell research in DP interview

The award named after German businessman Bernard Broermann, recognizes outstanding scientific achievements in the field of medical innovation and comes with €1 million in prize money. Read More

Next-generation CAR T cells could expand solid cancer treatment options

T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have struggled to adapt the treatment ... Read More

Penn’s CAR-T pioneer Carl June talks about the future of his award-winning work to train the body to fight cancer

Emily Whitehead, the first child cured of cancer with therapy from Penn, returns as a student. This summer your lab also published research on enhancing CAR-T cells for lymphoma. Can you talk about ... Read More

ESGCT 2025: Redefining CAR T cells across cancer and autoimmunity

As the many challenges facing cell therapies are being addressed, the CAR T field continues to evolve beyond its original design of T cells engineered to target hematological malignancies. During the ... Read More

How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care Playbook

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ... Read More

Advances in cancer treatment: CAR T cells fight solid tumors

A new generation of CAR T cell therapy is bringing hope in the fight against cancer, targeting not only blood cancers but also solid tumors such as ovarian and breast cancer. Fraunhofer researchers ... Read More

Enhanced CAR T cells emerge from genetic screening

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ... Read More

Mount Sinai researchers pioneer first targeted therapy for rare T-cell lymphoma after CAR T treatment

New York, NY (August 21, 2025) – A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma ... Read More

Revolutionizing CAR T-Cell Therapy to Improve Patient Access

CAR T-cell therapy demand is rising, prompting institutions to expand access and reduce care barriers, exemplified by Vanderbilt-Ingram Cancer Center's outpatient center. Dr. Oluwole emphasizes ... Read More

Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ... Read More

MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ... Read More